Innovations in the treatment of HER2-Positive metastatic breast cancer patients
Metastatic breast cancer (MBC) is the most wide-spread oncology disease between women. It is one of the most important reasons that lead to death in women population all over the world and in Russian Federation too. According to the wHo data, there are more than 11 million women with the MBC diagnosis. Every year 1.2 million of the new MBC cases are appeared and about 0.5 million are died. The aim of this research was to estimate in terms of the current clinical trials data the practicability of the new scheme (pertuzumab + trastuzumab) including to the treatment of HER2-Positive metastatic breast cancer patients.